Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267266 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL20272016 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL5968081 | 0.94 | PPM1B (0.45) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL6141464 | 0.92 | — | — | |
| SCHEMBL526510 | 0.92 | PPM1B (0.55) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL12947777 | 0.89 | ALDH1A1 (0.45) | PPM1BPTPN1PPP1CCALDH1A1HCAR2 | |
| SCHEMBL11776740 | 0.87 | NAAA (0.48) | ALDH1A1SMN1; SMN2HCAR2 | |
| SCHEMBL1297212 | 0.86 | MAPT (0.51) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL15071095 | 0.85 | NAAA (0.52) | SMN1; SMN2HCAR2 | |
| SCHEMBL1296724 | 0.84 | PPM1B (0.49) | PPM1BPTPN1PPP1CCALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | claimed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | claimed |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3551633-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018108230-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2018-06-21 | — | — | WO | disclosed |
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20160354471-A1 | Pine Bark Extract and Black Pepper Essential Oil with Anti-Inflammatory and Anti-Arthritic Action and Method of Preparing | CAVALLARO ANTONINO (US) | 2016-12-08 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9095607-B2 | Gel for topical application of clove essential oil with broad spectrum anti-inflammatory action and method of preparing same | CAVALLARO ANTONINO (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182578-A1 | GEL FOR TOPICAL APPLICATION OF CLOVE ESSENTIAL OIL WITH BROAD SPECTRUM ANTI-INFLAMMATORY ACTION AND METHOD OF PREPARING SAME | CAVALLARO ANTONINO (US) | 2015-07-02 | — | — | US | disclosed |
| WO-2015082034-A1 | USE OF CYCLOHEXANOIC ACID DERIVATIVES AS PLASTICIZERS | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013091775-A2 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE INGREDIENTS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | PPM1B 3305/4885PTPN1 3164/4885PPP1CC 4144/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | PPM1B 2880/4885PTPN1 3760/4885PPP1CC 2287/4885 |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | PPM1B 3305/4885PTPN1 3164/4885PPP1CC 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.